J&J expands product recall again
McNeil Consumer Healthcare, a division of Johnson & Johnson (J&J), has once again expanded the recall of certain OTC products because of a musty or moldy odor, which has been linked to trace amounts of the chemical 2,4,6 triburomoanisole (TBA).
McNeil Consumer Healthcare, a division of Johnson & Johnson (J&J), has once again expanded the recall of certain OTC products because of a musty or moldy odor, which has been linked to trace amounts of the chemical 2,4,6 triburomoanisole (TBA). The recall was originally announced in January 2010, but was extended to five additional product lots in June and then to a further 21 product lots last week. The full list of recalled products and lots can be found on McNeil’s recall website.
The contamination is believed to stem from the breakdown of a substance applied to wood, which is used to build pallets that transport and store packaging materials. In its latest statement regarding the recall, the company explained that it stopped accepting shipments of materials from its suppliers on that type of pallet after the recall was first announced. Since the first recall, however, it has been working with external suppliers to track down shipments involving the wooden pallets and then to tie them to specific lots of manufactured products.
The most recent lots have been added to the recall as a “precautionary measure” after J&J determined that some packaging materials used in them had been shipped and stored on the wooden pallets.
Fortunately, the risk of serious adverse medical events in response to the contamination is remote, according to a statement from J&J; however, the company said that it has received a few reports of gastrointestinal-related events, such as stomach discomfort.
The company has also been subject to heavy criticism since the recall was announced, including a reprimanding warning letter from the FDA in January.
There may also be further trouble ahead for the pharma giant regarding a product recall announced in April of certain OTC infants’ and children’s products as a handful of consumers have filed complaints seeking class-action statements. According to reports from Reuters and Bloomberg, the complaints accuse the company of “fraud and racketeering” for not recalling all of its children’s medicines and also for not offering consumers the opportunity to recover out-of-pocket expenses.
Read PharmTech’s related stories:
J&J Voluntarily Recalls Certain OTC Products
J&J Voluntarily Recalls Certain OTC Products Because of Manufacturing Problems
Five More Lots Added to January 2010 Tylenol and Benadryl Recall
FDA Testifies to Congress Regarding J&J Recalls, Quality Concerns
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
